How I treat Gaucher disease.

Area of Science:

• Biochemistry
• Genetics
• Clinical Medicine

Background:

• Gaucher disease (GD) presents a wide clinical spectrum, historically managed with a single enzyme replacement therapy (ERT).
• Recent ERT shortages necessitated a re-evaluation of GD treatment paradigms.
• Patient care involves complex interactions between patients, physicians, and insurers.

Purpose of the Study:

• To present a cohesive and evidence-based approach to managing Gaucher disease.
• To outline a practical strategy for optimizing ERT in GD patients.
• To address the challenges posed by ERT shortages and advocate for cost-effective treatments.

Main Methods:

• Accurate enzymatic diagnosis and mutation analysis for prognostication and carrier detection.
• Regular patient follow-up (6-12 months) with attention to comorbidities.
• Initiation of ERT based on symptomatic presentation or clinical deterioration.

Main Results:

• The study advocates for individualized ERT, avoiding treatment for very mild cases.
• Presymptomatic therapy is considered for high-risk individuals, such as young women with adverse obstetric histories.
• A preference for minimal-effective doses over maximally tolerated doses is highlighted to reduce societal burden.

Conclusions:

• Personalized treatment strategies are crucial for Gaucher disease management.
• Cost-effective approaches, including dose optimization, are ethically justified when clinical benefits are minimal.
• A multidisciplinary approach involving patients, physicians, and insurers is essential for optimal GD care.